On July 27, 2020 Immodulon, the immuno-oncology company, reported an expansion to its ongoing collaboration with Professor van Eijck and his team at the Erasmus University Medical Center Rotterdam ("Erasmus MC") (Press release, Immodulon Therapeutics, JUL 27, 2020, View Source [SID1234562740]). A phase I/II, open label study is being planned in patients with limited metastatic pancreatic cancer ("MEPANC -1") . The trial is designed to evaluate the safety and efficacy of IMM-101 administered in combination with stereotactic radiotherapy of metastases in the liver and lung in patients with limited metastatic pancreatic cancer. This follows the successful recruitment of 20 patients in a separate phase I/II study combining IMM-101 with stereotactic radiotherapy in locally advanced pancreatic cancer ("LAPC-2"). The MEPANC -1 study design will be submitted to the local Erasmus MC Medical Ethics Review Committee and the national Central Committee on Research Involving Human Subjects(CCMO) and, should it be approved, recruitment is expected to begin by the end of 2020.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Professor Casper H J van Eijck, hepatobiliary surgeon and Professor in surgery, commented:
"We look forward to starting this new original study which has not been performed before in patients with limited metastatic pancreatic cancer. Since the recruitment in the LAPC-2 study is highly successful, we expect to include patients from all Dutch Pancreatic Cancer Group hospitals within the allocated time frame. We are pleased that Immodulon is providing us with the IMM-101 study drug again and their support and hope that combining IMM-101’s positive effects on the immune system in combination with radiotherapy will lead potentially to a major step forward in the search of new and effective treatments for pancreatic cancer."
Dr. Jaap Kampinga, Chief Executive Officer of Immodulon, commented:
"We are pleased with the progress of our collaboration with Professor van Eijck and his team at this Centre of Excellence for pancreatic cancer at Erasmus MC. The MEPANC -1 study, testing our lead drug candidate, IMM-101, in limited metastatic pancreatic cancer, is designed to complement the ongoing LAPC-2 study. We look forward to the potential initiation of the MEPANC -1 study before the end of 2020, pending approval from local and national regulatory authorities. Pancreatic cancer is a devasting disease and remains exceedingly challenging to treat effectively, despite the advances in other cancer treatments."